Media releases

Please seek advice from your health professional about treatments for hearing loss. Outcomes may vary, and your health professional will advise you about the factors which could affect your outcome. Always follow the directions for use. Not all products are available in all countries. Please contact your local Cochlear representative for product information.

For a full list of Cochlear’s trademarks, please visit our Terms of Use page.

In Australia, Cochlear™ Nucleus® implant systems are intended for the treatment of moderately severe to profound hearing loss.

In Australia, Baha® bone conduction implant systems are intended for the treatment of moderate to profound hearing loss.

In Australia, the Cochlear™ Osia® System is indicated for patients with conductive, mixed hearing loss and single-sided sensorineural deafness (SSD) aged 10 years and above with up to 55 decibels sensorineural hearing loss. Patients should have sufficient bone quality and quantity to support successful implant placement. Surgery is required to use this product. Any surgical procedure carries risk.

For Cochlear™ Nucleus®, Osia® and Baha® systems: This product is not available for purchase by the general public. For information on funding and reimbursement please contact your health care professional.

Any testimonial featured on this website is intended for an Australian audience only.